Abstract：Objective: To observe the serum lipase (LPS) and serum amyloid (SAA) expression in patients with acute pancreatitis of different severity,and analyze the application of the above serum indicators in the early assessment of patients with severe acute pancreatitis,with the aim of guiding the early treatment of patients with clinical severe acute pancreatitis and promoting benign patient outcomes. Methods: Retrospectively,baseline data of 50 patients with mild acute pancreatitis admitted to our hospital between January 2018 and January 2022 were collected and included in the mild disease group (APACHE II score <8),and baseline data of 55 patients with severe acute pancreatitis during the same period were collected and included in the severe disease group (APACHE II score ≥8),and the baseline data of the two groups were compared with serum SAA and LPS expression,and the application of the above serum indicators in the early assessment of patients with severe acute pancreatitis was analyzed. Results: There was no statistically significant difference between the age,combined hypertension,combined diabetes mellitus,combined hyperlipidemia,and gender data of the two groups (P>0.05); compared with the mild disease group,the patients in the severe disease group showed high expression of serum SAA and LPS and higher APACHE II score,and the differences were statistically significant (P<0.05); multiple logistic regression model was established,and the results showed that the expression of serum SAA and LPS before treatment was related to the severity of acute pancreatitis patients,and overexpression of serum SAA and LPS might be a risk factor for aggravation of acute pancreatitis patients (OR>1,P<0.05); the ROC curve was plotted,and the results showed that the AUC of serum SAA and LPS expression before treatment to predict heavy disease in acute pancreatitis patients were all >0.80,and the predictive value were good.The results of bivariate Spearman linear correlation analysis showed that there was a positive correlation between the pre-treatment serum SAA and LPS expression and APACHE II score in patients with acute pancreatitis. Conclusion: Serum SAA and LPS can be used for the early assessment of patients with heavy acute pancreatitis,and patients with acute pancreatitis with high serum SAA and LPS expression should be considered as heavy,and the corresponding clinical treatment should be carried out immediately to promote a favorable prognosis of patients in the future.
黄丽丽, 韩能, 李树锦. 血清脂肪酶SAA表达在重型急性胰腺炎早期评估中的应用[J]. 河北医学, 2023, 29(7): 1110-1113.
HUANG Lili, HAN Neng, LI Shujin. Application of Serum Lipase and SAA Expression in the Early Assessment of Severe Acute Pancreatitis. HeBei Med, 2023, 29(7): 1110-1113.
[1] Lara L F,Nemer L,Hinton A,et al.Acute and severe acute pancreatitis and the effect of cannabis in states before and after legalization compared with states without legalized cannabis[J].Pancreas,2021,50(5):766-772. [2] Cgg A,Sf B,Gp C,et al.COVID-19,what could sepsis,severe acute pancreatitis,gender differences and aging teach us[J].Cytokine,2021,148(8):155628. [3] 胡小丽,刘哲,邓茂林.SAA,CRP和ACE2水平与急性胰腺炎患者病情严重程度的关系[J].西部医学,2021,33(3):440-443. [4] 赵凯,韩思静,任书勤,等.血清载脂蛋白B/载脂蛋白A1,脂蛋白a,脂肪酶水平预测重症急性胰腺炎的价值[J].郑州大学学报:医学版,2022,57(6):849-853. [5] 中华医学会消化病学分会胰腺疾病学组.中国急性胰腺炎诊治指南(草案)[J].现代消化及介入诊疗,2007,12(3):59-62. [6] Mann S L,Marshall M R,Woodford B J,et al.Predictive performance of acute physiological and chronic health evaluation releases Ⅱ to IV:a single new zealand centre experience.(Report)[J].Anaesth Intensive Care,2012,40(3):479-489. [7] 罗石磊,李宏,吴秦岭.急性胰腺炎患者血清生化因子水平变化及其临床意义[J].热带医学杂志,2021,21(6):762-764,769. [8] 丁晓琳,张伦军,高洁,等.血清脂肪酶,淀粉酶及C反应蛋白联合检测对急性胰腺炎诊断的意义[J].蚌埠医学院学报,2021,46(9):1255-1257. [9] 蒋忠洋,孙欢,马世伟,等.MSCT联合血清脂肪酶,淀粉酶检测对重型急性胰腺炎的诊断效能研究[J].中国CT和MRI杂志,2022,28(7):110-111,123. [10] 杨舒钧,梁红亮,滕俊,等.血清SAA,CRP,ACE 2对重症胰腺炎的临床诊断价值分析[J].标记免疫分析与临床,2021,28(12):2070-2073.
2023, Vol. 29 
冀公网安备13080202000677号